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A multifactorial ‘Consensus Signature’ by in silico analysis
to predict response to neoadjuvant anthracycline-based
chemotherapy in triple-negative breast cancer
Natalie Turner1,4, Mattia Forcato2,4, Simona Nuzzo2, Luca Malorni1,3, Silvio Bicciato2,5 and Angelo Di Leo1,5
BACKGROUND: Owing to the complex processes required for anthracycline-induced cytotoxicity, a prospectively deﬁned
multifactorial Consensus Signature (ConSig) might improve prediction of anthracycline response in triple-negative breast cancer
(TNBC) patients, whose only standard systemic treatment option is chemotherapy.
AIMS: We aimed to construct and evaluate a multifactorial signature, comprising measures of each function required for
anthracycline sensitivity in TNBC.
METHODS: ConSigs were constructed based on ﬁve steps required for anthracycline function: drug penetration, nuclear
topoisomerase IIα (topoIIα) protein location, increased topoIIα messenger RNA (mRNA) expression, apoptosis induction, and
immune activation measured by, respectively, HIF1α or SHARP1 signature, LAPTM4B mRNA, topoIIα mRNA, Minimal Gene signature
or YWHAZ mRNA, and STAT1 signature. TNBC patients treated with neoadjuvant anthracycline-based chemotherapy without taxane
were identiﬁed from publicly available gene expression data derived with Affymetrix HG-U133 arrays (training set). In silico analyses
of correlation between gene expression data and pathological complete response (pCR) were performed using receiver-operating
characteristic curves. To determine anthracycline speciﬁcity, ConSigs were assessed in patients treated with anthracycline plus
taxane. Speciﬁcity, sensitivity, positive and negative predictive value, and odds ratio (OR) were calculated for ConSigs. Analyses were
repeated in two validation gene expression data sets derived using different microarray platforms.
RESULTS: In the training set, 29 of 147 patients had pCR after anthracycline-based chemotherapy. Various combinations of
components were evaluated, with the most powerful anthracycline response predictors being ConSig1: (STAT1+topoIIα mRNA
+LAPTM4B) and ConSig2: (STAT1+topoIIα mRNA+HIF1α). ConSig1 demonstrated high negative predictive value (85%) and high OR
for no pCR (3.18) and outperformed ConSig2 in validation sets for anthracycline speciﬁcity.
CONCLUSIONS: With further validation, ConSig1 may help reﬁne selection of TNBC patients for anthracycline chemotherapy.
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INTRODUCTION
Preferred breast cancer (neo)adjuvant chemotherapy regimens are
generally anthracycline based, given the improved outcomes
compared with cyclophosphamide/methotrexate/ﬂuorouracil.1
However, across all anthracycline-treated patients, only a small
percentage actually receives beneﬁt while these agents are
associated with signiﬁcant toxicities. Breast cancer is well
recognized as a heterogeneous disease and therefore treating
all breast cancers with the same chemotherapeutic agents could
be considered illogical. Of considerable use would be a predictive
marker of response to distinguish patients likely to receive beneﬁt
from those who are not, sparing predicted ‘poor responders’ from
associated toxicities. Unfortunately, suitable predictive biomarkers
for chemotherapeutic agents have remained elusive to date.
Topoisomerase IIα gene (TOP2A) is a putative marker of
anthracycline sensitivity, with its gene product being the direct
target of anthracyclines. TOP2A ampliﬁcation has been shown to
predict increased sensitivity to anthracyclines in several studies,2–7
although this ﬁnding has not been entirely consistent.8,9 Indeed, a
single biomarker may not be sufﬁcient to predict anthracycline
response, and a multifactorial approach using gene signatures
might be required.7,10 In the TOP trial7 of 149 patients with
estrogen receptor (ER)-negative early or locally advanced breast
cancer treated with a single agent epirubicin, TOP2A ampliﬁcation
was signiﬁcantly associated with pathological complete response
(pCR). In addition, a multifactorial anthracycline sensitivity score
(the A-score), comprised of three gene signatures, was evaluated,
demonstrating a very high negative predictive value (NPV),
although a much lower positive predictive value (PPV).7
Gene signatures are often deﬁned through retrospective
analyses of tumor tissue gene expression patterns correlated with
patient outcomes. Although concordance in outcome prediction
between signatures has been demonstrated,11 signatures derived
in this manner often contain few genes in common as well as
numerous genes of unknown function, making their clinical
relevance less certain. It might be possible to improve clinical
relevance of a signature by identifying the molecular processes
required for a speciﬁc cellular function, such as anthracycline-
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induced cytotoxicity, and construct a signature containing mea-
sures of each of these functions. On the basis of this hypothesis,
we aimed to construct and evaluate a multifactorial Consensus
Signature for predicting anthracycline sensitivity in triple-negative
breast cancer (TNBC). The term Consensus Signature was chosen
to reﬂect the concept that, by each selected component acting as
a surrogate marker of the different steps required for anthracy-
cline cytotoxicity, included components (the genes and gene
signatures) would work synergistically to provide an overall
measure of effective anthracycline function.
We focused speciﬁcally on TNBC for the following reasons. First,
there has been substantial work performed already evaluating the
predictive role of TOP2A in HER2+ breast cancer, due to the known
relationship between TOP2A ampliﬁcation and HER2 ampliﬁcation.
Anthracyclines are commonly used in TNBC and appear to have
activity. We wanted to assess this without the confounding factor
of HER2 overexpression. Second, with treatment options in TNBC
limited to chemotherapy, more effective use of chemotherapy
would be of considerable beneﬁt. Finally, with growing under-
standing of breast cancer biological diversity, evaluation of a
predictive biomarker within a speciﬁc subtype might be prefer-
able, as positive results could otherwise be masked if evaluated
across a heterogeneous combined cohort.
MATERIALS AND METHODS
Data set
The construction and evaluation of consensus signatures (ConSigs) were
carried out using a retrospective cohort study design, with in silico analyses
of previously collected genetic data, clinical characteristics, and responses.
The data set comprised gene expression proﬁles of patients who had
received neoadjuvant anthracycline-based chemotherapy without a
taxane. As the ConSigs were designed to be speciﬁc for anthracyclines,
taxane use was considered a confounding factor.
Data derived from Affymetrix (Santa Clara, CA, USA) gene expression
arrays based on build 133 of UniGene database (HG-U133) were combined
and evaluated as a single group, designated the ‘breast compendium’
(details on the construction and composition of the breast compendium
are reported in Supplementary Table 1). The subset of samples treated
with anthracycline-based neoadjuvant chemotherapy was used as training
set to derive the ConSigs, whereas the cohort of patients treated with
anthracycline plus taxane-based neoadjuvant chemotherapy served as a
control group to assess ConSig speciﬁcity for anthracyclines. In addition,
two cohorts of patients treated with anthracycline-based neoadjuvant
chemotherapy with gene expression data derived from different micro-
array platforms served as validation sets. The European Organisation for
Research and Treatment of Cancer (EORTC)/BIG00-01 data set included
gene expression data obtained with the Affymetrix X3P array from patients
with locally advanced, inﬂammatory, or large operable breast cancers
treated with either ﬂuorouracil/epirubin/cyclophosphamide or docetaxel
followed by docetaxel/epirubicin under the auspices of the EORTC 10994
trial.12 The data set was available in the Gene Expression Omnibus
repository under accession number GSE6861. The Netherlands Cancer
Institute (NKI) data set (accessible under accession number GSE34138)
used the Illumina (San Diego, CA, USA) HumanWG 6 v3.0 expression
beadchip for gene expression proﬁling and included patients with
intermediate or high-risk ER-breast cancer treated with neoadjuvant
dose-dense doxorubicin/cyclophosphamide.13
For this study, only TNBC patients in the training and control subsets of
the compendium and in the validation sets were considered. Further
details on the construction of the breast compendium and on the
deﬁnition of TNBCs are reported in the Supplementary Methods.
Design of the consensus signature
In order for anthracyclines to be effective, we postulated that the following
steps must occur: (1) penetration of the drug into the tumor bed, (2)
location of the target (topoIIα protein) within the nucleus, (3) increased
topoIIα messenger RNA (mRNA) expression above that related to
proliferation alone, (4) induction of apoptosis, and (5) active immune/
stromal function.
For each step, a representative gene or gene signature was selected,
with gene signatures chosen over single genes where possible. In some
cases, more than one potential genes/gene signatures was evaluated for
each step, to compare their relative utility. Details of the marker(s)
evaluated, their association with anthracycline response, and rationale for
their selection are listed in Table 1.
Quantiﬁcation of genes and gene signatures
SHARP1 signature,14 HIF1α hypoxia signature (HIF),14 and the Minimal
Gene signature15 were quantiﬁed as previously described. Brieﬂy, each
signature was calculated by summarizing the standardized expression
levels of the genes in the signature into a combined score with zero mean.
AURKA, STAT1, and PLAU signatures were computed as previously
described16 using genefu R package. Brieﬂy, for each sample, the signature
was quantiﬁed as: s=Σiωiξi/Σi|ωi| where ξI is the expression of a gene i
included in the set of genes of interest and ωI is either +1 or − 1 depending
on the sign of the association under study. Gene expression lists for each
signature are included in Supplementary Table 2.
LAPTM4B, AURKA, YWHAZ, and topoIIα mRNA expression levels were
calculated using the corresponding probe sets or the median expression if
multiple probe sets were available for each gene. For the NKI data set,
probes were ﬁltered on the basis of their quality, keeping only probes
classiﬁed as ‘perfect’ and ‘good’ in the Bioconductor illumina Human v3.db
annotation package.
Quantiﬁcation of the Consensus Signature
The Consensus Signature score was calculated in a continuous form,
consisting of a linear combination of the various components/signatures.
Prior to combination, each component/signature was scaled to have the
interquartile range equal to 1 and the median equal to 0. On the basis of
the association with pCR (Table 1), we hypothesized that a high Consensus
Signature score would predict for increased pCR rate, whereas a low score
should predict anthracycline resistance.
Statistical analysis
All statistical analyses were performed in R version 2.15.1.17 Odds ratios
(ORs) were used to compare pCR rates between groups deﬁned by
different clinical and molecular characteristics (stats R package). The area
under the curve (AUC) was used to assess the prediction performance of
any signature score (ROCR R package). AUC was estimated through the
concordance index (survcomp R package) under the alternative hypothesis
that AUC was greater than 0.5, as each signature score was designed to
have positive AUC. Its signiﬁcance and conﬁdence interval were estimated
assuming asymptotic normality. Because of the differences in array design
and technology between the training and the two validation sets, the
threshold ConSig score for each cohort was calculated using the score
value that corresponded to the 75th percentile of the score distribution for
that cohort. P values of o0.05 were considered signiﬁcant.
RESULTS
Data set
The training set was derived from a breast cancer data set
originally consisting of 4,600 samples collected in 27 different
studies. After exclusion of duplicate samples (n= 939) and
adjusting for batch effect using ComBat,17 1,069 samples (29%)
were classiﬁed as TNBC by the SCMOD2 subtype clustering
classiﬁer (subtype clustering model)18 contained in genefu R
package.19 Among these samples, 491 had information about
neoadjuvant chemotherapy. Eleven samples were from patients
treated with taxane but not anthracycline and were excluded,
whereas 147 and 333 samples were from patients treated with
anthracycline-based therapy without taxane and anthracycline-
based therapy with taxane, respectively (Figure 1).
Clinical and tumor characteristics for the patients in the training
set (n= 147) treated with anthracycline-based chemotherapy are
listed in Table 2. The samples were originally contained in four
different data sets,7,20–22 and included 29 (19.7%) pCRs and 118
(80.3%) samples with residual disease. pCR was deﬁned as ypT0/is,
ypN0 in all included studies.
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Clinical characteristics
All clinical variables were tested for their ability to predict pCR,
with no signiﬁcant association between any clinical characteristics
and pCR found (data not shown).
Predictive power of single gene or gene signatures
Using receiver-operating characteristic curves, the ability of any
single component (gene or gene signature) to discriminate
patients with pCR from patients with residual disease in the
training set was assessed. STAT1 was signiﬁcantly associated with
pCR status (Supplementary Table 3; Supplementary Figure 1a). All
other components, when considered individually, were not
signiﬁcantly correlated with pCR. TopoIIα mRNA corrected for
proliferation with either AURKA mRNA or AURKA signature
showed no increased correlation with pCR compared with topoIIα
mRNA alone (data not shown).
Predictive power of ConSigs
ConSigs was constructed using various combinations of compo-
nents, with the starting point being components shown to
have signiﬁcant or near-signiﬁcant predictive capability when
Table 1. Consensus Signature components based on putative steps required for effective anthracycline-induced cytotoxicity
Step Surrogate marker Association with
pCR
Rationale
Penetration of drug into
the tumor bed
SHARP1 signature
Hypoxia signature
(HIF)
Negative
Negative
Hypoxia, promoted by HIFs, is a well-known contributor to decreased drug
penetration, and chemoresistance.1 Montagner et al. recently described a
hypoxia signature of 22 genes, with increased expression correlated with
increased HIF activity.2 A direct interaction between SHARP1 (a downstream
target of the tumor suppression gene p63) and HIF1α and HIF2α was
demonstrated, with a signature of low SHARP1 activity in TNBC conferring
increased HIF function and increased hypoxia.2 With the SHARP1 signature
measuring low SHARP activity and thus increased HIF function, it has a negative
association with pCR.
Location of topoIIα protein
within the nucleus
LAPTM4B Negative In order to work effectively, the target of anthracyclines, topoIIα protein, must
have access to nuclear DNA; thus, it must be located in the nucleus. Nuclear
export of topoIIα protein may contribute to anthracycline resistance.3,4 topoIIα
protein nuclear location might be inferred using the expression level of
LAPTM4B.5 LAPTM4B gene resides on chromosome 8q22, with overexpression
shown to increase sequestration of anthracyclines in the cytoplasm. Increased
levels of LAPTM4B mRNA have been correlated with increased anthracycline
resistance, whereas selective depletion of LAPTM4B signiﬁcantly increased
sensitivity to anthracycline, but not cisplatin or taxane, chemotherapy.5
Increased expression
of topoIIα mRNA,
independent of
proliferation
topoIIα mRNA
topoIIα mRNA: AURKA
topoIIα mRNA: AURKA
signature
Positive
Positive
Positive
TOP2A transcription can be enhanced by proliferation signals independently of
gene aberrations and topoIIα protein is strongly inﬂuenced by proliferation.6
Increased expression of topoIIα protein therefore may be seen in the setting of
highly proliferating tumors, without correlating with an increased likelihood of
response speciﬁcally to anthracyclines. By determining the ratio of expression of
topoIIα mRNA relative to that of a known proliferation marker (Aurora kinase A
gene, AURKA,7,8 or AURKA gene signature), tumors with increased topoIIα mRNA
independent of proliferation might be determined.
Induction of apoptosis YWHAZ
Minimal gene
signature (MS)
Negative
Positive
The anti-apoptotic gene YWHAZ (coding for 14-3-3ζ) resides on chromosome
8q22 close to LAPTM4B gene and may promote de novo anthracycline
resistance.5 Increased expression has been associated with increased
doxorubicin resistance in breast cancer cell lines, and early relapses after
anthracycline chemotherapy. siRNA knockdown of YWHAZ in breast cancer cell
lines signiﬁcantly increased doxorubicin-induced apoptosis.5 An alternate
marker of apoptosis is the MS,9 comprising two genes, SHARP1 and CCNG2. As
with SHARP1, CCNG2 is a downstream target of p63. As p63 is inhibited by
mutant p53, lack of MS expression implies dysfunction in the p53 pathway, the
major apoptotic pathway in the presence of oncogenic stress, and may be a
suitable surrogate for lack of apoptosis.
Active immune function Immune function
signature (STAT1)
Stromal signature
(PLAU)
Positive
Negative
Both innate and adaptive immune responses are important in anthracycline
toxicity.10–13 Anthracyclines trigger immunogenic cell death by eliciting tumor-
speciﬁc IFNγ CD8+ cytotoxic T lymphocytes, thus an anthracycline-induced
anticancer immune response can help eradicate residual cancer cells, or maintain
residual cells in state of dormancy. Moreover, immune module scores14,15 have
been associated with higher probability of achieving pCR after anthracycline±
taxane chemotherapy among all breast cancer subtypes when deﬁned by
immunohistochemistry.16 Closely related to immune function, stromal signatures
may also be useful in predicting anthracycline sensitivity or resistance.15,17
Abbreviations: HIF, hypoxia-inducible factor; IFNγ, interferon gamma; LAPTM4B, lysosomal-associated protein transmembrane 4B gene; mRNA, messenger
RNA; MS, minimal gene signature; pCR, pathological complete response; siRNA, small interfering RNA; TNBC, triple-negative breast cancer.
References for this table are listed in Supplementary Materials.
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used alone, that is, STAT1, topoIIα, HIF, and LAPTM4B. Using
a continuous score to quantify ConSig expression level, all
combinations of core components demonstrated a signiﬁcant
correlation with pCR in patients in the training set treated with
anthracycline-based chemotherapy without taxane. The two
most predictive combinations were designated ConSig1: (STAT1
+topoIIα+LAPTM4B) with AUC 0.70 (Supplementary Figure 1b),
P= 3.9 × 10− 5, and ConSig2: (STAT1+topoIIα+HIF) with AUC 0.71,
P= 4.2 × 10− 6. High correlation with pCR was maintained with the
addition of further component genes/gene signatures to either
ConSig1 or ConSig2, but overall predictive power was not better
than with three components (Table 3). The combination of STAT1
+PLAU, the components for TNBC of another multifactorial scoring
signature, the A-score,7 was correlated with pCR, although less
strongly than other combinations. Substituting topoIIαmRNA with
topoIIα mRNA corrected for proliferation did not improve the
performance of any of the ConSigs.
To assess speciﬁcity of ConSigs for anthracycline response
compared with other chemotherapy regimens, we analyzed their
respective performances in a control group of patients who received
taxane in addition to anthracycline (n=333), 299 of whom had
information about response and 101 with pCR. For the ConSigs with
the highest predictive power in the training set, i.e., ConSig1 and
ConSig2, neither was correlated with pCR in this control group
(Supplementary Figure 1c and d). Although (STAT1+PLAU) had
predicted response to anthracycline-based chemotherapy, it did not
appear to be anthracycline speciﬁc, performing similarly in
anthracycline+taxane-treated patients (Table 3).
Classiﬁcation performance of ConSigs
A threshold score that could be used to classify a patient in the
training set as a putative responder or as resistant was determined
for each ConSig by selecting the score value corresponding to the
75th percentile of the score distribution. PPV and NPVs, sensitivity,
speciﬁcity, and OR were then calculated. For ConSig1 NPV was
high (85%) as was OR for lack of pCR (OR = 3.18, P= 0.008)
(Table 4). PPV, however, was modest (PPV= 35%). ConSig2
performed similarly, with high NPV and OR, but modest PPV. In
the control group of 299 patients treated with anthracycline plus
taxane, NPVs for ConSig1 and ConSig2 were lower, at 66 and 67%,
respectively, and ORs for lack of pCR were no longer statistically
signiﬁcant for either ConSig (Table 4), further supporting the
speciﬁcity of these ConSigs for anthracycline response.
Evaluation of ConSig1 and ConSig2 in two independent ‘validation’
data sets
Two data sets, NKI and EORTC/BIG00-01, were selected as
validation sets. The EORTC/BIG00-01 data set12 comprised 161
samples, 85 of which were TNBC, with 46 patients treated with
anthracycline without taxane (18 pCRs) and 39 treated with
anthracycline plus taxane (18 pCRs). The NKI data set13 included
178 ER-negative breast cancer samples, 52 of which were TNBC. Of
these 52 patients, 24 had pCR. All patients received anthracycline-
based neoadjuvant chemotherapy without taxane.
In the NKI data set, both ConSig1 and ConSig2 were signi-
ﬁcantly correlated with pCR for patients receiving anthra-
27 BC studies with gene
expression profiles
N=4600
Duplicates
N=939
No NAC data
N=578
Non-TNBC
N=2592
T without A
N=11
N=3661
TNBC/Basal-like
N=1069
NAC data available
N=491
A + T-based NAC with known
response
N=299
A-based NAC
N=147
No pCR
N=118
pCR
N=29
pCR
N=101
No pCR
N=198
A + T-based NAC
N=333
Response to NAC
unknown
N=34
Figure 1. Consort diagram for selection of samples in the training set. A, anthracycline-based chemotherapy; BC, breast cancer; NAC,
neoadjuvant chemotherapy; pCR, pathological complete response; T, taxane; TNBC, triple-negative breast cancer.
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cycline without taxane (Table 5). In the EORTC/BIG00-01
data set, ConSig1 remained speciﬁc for anthracyclines in the
data set, whereas ConSig2 was correlated with pCR for both
anthracycline-based and anthracycline+taxane-based neoadju-
vant chemotherapy.
DISCUSSION
Overall, the best performing combination of components was
ConSig1 (STAT1+topoIIα+LAPTM4B). Our results suggest that Con-
Sig1 has excellent ability to predict anthracycline resistance within a
cohort of anthracycline-treated TNBC patients. This is clinically
relevant, as, if further validated, ConSig1 could be used to identify
TNBC patients for whom the addition of anthracycline is likely to add
toxicity without beneﬁt, and thus for whom an alternate
chemotherapy regimen might be selected. When evaluated in TNBC
patients who received anthracycline and taxane, the predictive
ability of ConSig1 was lost. Although not conclusive, a lack of
predictive utility in patients who also received taxanes supports the
anthracycline speciﬁcity of ConSig1. ConSig2 was most strongly
correlated with pCR in the training set; however, in the validation set
ConSig2 did not show discrimination in performance between
patients treated with anthracycline-based and anthracycline plus
taxane-based neoadjuvant chemotherapy.
Although we considered that ﬁve main processes should take
place for anthracyclines to cause cell death, markers for two of
these processes, that is, induction of apoptosis and hypoxia/drug
penetration, did not appear to contribute signiﬁcantly to the
predictive power of ConSig1. Given that immune function (STAT1)
was a powerful contributor to ConSig1 and ConSig2, we postulated
that in the setting of a highly active immune response, intact
apoptotic pathways as measured by Minimal Gene signature15 or
Table 2. Clinical and tumor characteristics of TNBC patients in the
training set treated with anthracycline-based neoadjuvant
chemotherapy without taxane (n= 147)
Characteristic No. of patients (%)
Age (years)
o40 12 (8)
40–60 40 (27)
460 7 (5)
NA 88 (60)
Tumor size
T1 15 (10)
T2 90 (61)
T3 22 (15)
T4 19 (13)
NA 1 (1)
Nodal status
N0 14 (9)
N1 13 (9)
N2 6 (4)
NA 114 (78)
Histologic grade
G1 2 (1)
G2 25 (17)
G3 112 (76)
NA 8 (6)
pCR
Yes 29 (20)
No 118 (80)
Abbreviations: NA, not available; pCR, pathological complete response;
TNBC, triple-negative breast cancer.
Table 3. Correlation with pCR for various combinations of ConSig components in the training set
ConSig combination Type of NAC AUC 95% CI P value
STAT1+PLAU A 0.63 0.52–0.73 9.0 × 10− 3
A+T 0.56 0.50–0.63 3.1 × 10− 2
STAT1+topoII A 0.68 0.57–0.78 7.6 × 10− 4
A+T 0.60 0.54–0.67 1.2 × 10− 3
STAT1+topoIIα+LAPTM4B (ConSig1) A 0.70 0.60–0.80 3.9 × 10− 5
A+T 0.55 0.48–0.61 0.08
STAT1+topoIIα+HIF1 (ConSig2) A 0.71 0.62–0.80 4.2 × 10− 6
A+T 0.52 0.45–0.58 0.33
STAT1+topoIIα+YWHAZ A 0.66 0.56–0.76 6.8 × 10− 4
A+T 0.54 0.48–0.61 0.10
STAT1+topoIIα+LAPTM4B+YWHAZ A 0.66 0.56–0.76 8.0 × 10− 4
A+T 0.51 0.45–0.58 0.34
STAT1+topoIIα+LAPTM4B+MS+PLAU A 0.62 0.51–0.72 1.3 × 10− 2
A+T 0.56 0.49–0.62 4.2 × 10− 2
Abbreviations: AUC, area under the ROC curve; CI, conﬁdence interval; ConSig, Consensus Signature; HIF, hypoxia-inducible factor; LAPTM4B, lysosomal-
associated protein transmembrane 4B gene; MS, minimal gene signature; NAC, neoadjuvant chemotherapy; pCR, pathological complete response;
ROC, receiver-operating characteristic.
For A-based chemotherapy, n= 147 with 29 pCRs. For A+T chemotherapy, n= 299 with 101 pCRs.
A: anthracycline-based neoadjuvant chemotherapy without taxane; A+T: anthracycline plus taxane neoadjuvant chemotherapy.
Table 4. Performance of ConSig1 and ConSig2 in the training set for
predicting pathological complete response
ConSig NAC NPV (%) PPV (%) OR 95% CI P value
ConSig1 A 85 35 3.18 1.34–7.54 8.2 × 10− 3
A+T 66 35 1.05 0.60–1.82 0.85
ConSig2 A 85 32 2.63 1.10–6.20 2.8 × 10− 2
A+T 67 37 1.23 0.71–2.12 0.45
Abbreviations: A, anthracycline-based chemotherapy; A+T, anthracycline
+taxane chemotherapy; CI, conﬁdence interval; ConSig, Consensus
Signature; NAC, neoadjuvant chemotherapy; NPV, negative predictive
value; OR, odds ratio for lack of pathological complete response; PPV,
positive predictive value.
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YWHAZ23 might be less important. However, predictive power was
not improved using either Minimal Gene signature or YWHAZ in
absence of the immune/stromal components (STAT1 and PLAU)
(data not shown). Although the inclusion of a component marker
of hypoxia had the highest correlation with pCR in the training set
(ConSig2), this combination did not show consistent anthracycline
speciﬁcity, with similar performance in anthracycline- and
anthracycline plus taxane-treated patients in the EORTC validation
set. This might be because hypoxia is a critical factor in the
function of other chemotherapy agents, not only anthracyclines.
Interestingly, although topoIIα protein expression is known to
relate to proliferation,24 correcting topoIIα mRNA expression level
for proliferation made no difference to the predictive utility of the
ConSigs. The lack of discriminating ability of the proliferative
markers, AURKA or AURKA signature, might relate to the fact
that the majority of tumors in our data set (76%) were grade 3
with most of the rest being grade 2, and thus were all moderately
to highly proliferating. With no comparator group of low-
proliferating tumors, the inﬂuence of a proliferation marker
cannot easily be evaluated. Furthermore, when considering a
cohort of TNBC, proliferation is characteristically high, making the
ability to measure variability of topoIIα protein expression due to
low versus high proliferation arguably less critical. Although the
inﬂuence of proliferation itself in the results is uncertain, the
speciﬁcity of ConSig1 for anthracycline response over and above
that of proliferation is supported by the fact that it is not
predictive in patients treated with anthracyclines plus taxanes, a
situation where proliferation is still important.
Differently from the A-score, which evaluated ER-/HER2+ and
ER-/HER2− tumors, we focused speciﬁcally on TNBC, a group
where treatment is limited to chemotherapy, and thus where
optimization of chemotherapy regimen would be of considerable
utility. Interestingly, the predictive ability of ConSig1 for TNBC
patients treated with anthracycline-based chemotherapy without
taxane appeared to be better than the combination of STAT1
+PLAU, the component gene signatures in the A-score for TNBC.
By constructing a biologically relevant multifactorial ConSig, we
hypothesized that this should predict anthracycline response, as
well as resistance; however, PPV of all ConSigs in the training set
were lower than anticipated, and only around 35% for ConSig1.
Conversely, ConSig1 predicts likelihood of lack of response (NPV),
which is still a ﬁnding of considerable clinical utility if further
validated. In general, high PPV for biomarkers has previously been
shown to be hard to achieve. Considering two well-established
biomarkers and the only two routinely used in breast cancer
management, ER and HER2, positivity predicts treatment response
in only around 50% of patients for endocrine therapy25 and less
than 40% for trastuzumab as a single agent.26 However, it is worth
noting that the small number of pCRs in the training set (29/147;
19.7%) might have contributed to less than stable results for
PPV. Indeed, in the validation sets, where pCR rates are 39%
(EORTC/BIG00-01) and 46% (NKI), PPV is higher than 75% (Table 5).
Finally, our sample size was relatively limited. The training set
used contained all publicly available data on the same platform for
TNBC treated with anthracycline-based chemotherapy. However,
this incorporated only 147 TNBC patients. Thus, further validation
of ConSig1 in independent TNBC cohorts is necessary.
In conclusion, this project demonstrated the feasibility of deﬁning
a multifactorial Consensus Signature for predicting anthracycline
response and, when applied in a TNBC patient cohort, ConSig1 was
highly predictive for anthracycline resistance. With further validation,
this signature may provide clinicians with a useful tool for improved
selection of TNBC patients for anthracyclines, potentially leading to
better treatment tolerance and more effective therapy.
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